BI 754132
Alternative Names: BI-754132Latest Information Update: 28 Aug 2022
At a glance
- Originator Boehringer Ingelheim
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
- 03 May 2022 Boehringer Ingelheim suspends a phase I trial in Age-related macular degeneration in USA (Intravitreous) due to COVID-19 pandemic (NCT04002310)
- 27 May 2020 Boehringer Ingelheim re-initiates a phase I trial in Age-related macular degeneration in USA (Intravitreous) (NCT04002310)